Jazz Pharmaceuticals plc (JAZZ) Earnings Call Transcripts
Jazz Pharmaceuticals plc's Latest Earnings Call - May 27, 2026
In the Q1 2026 earnings call, Jazz Pharmaceuticals plc (JAZZ:US) highlighted significant advancements in their oncology pipeline, particularly with zanidatamab and Zepzelca. The company reported strong momentum in their oncology business, with zanidatamab receiving breakthrough designation and a PDUFA date set for August 25, 2026. Management expressed confidence in the upcoming launch of zanidatamab for frontline gastric cancer, anticipating strong demand due to its efficacy in both PD-L1 positive and negative patients. Revenue growth is expected to be driven by the successful launch of zanidatamab and continued performance of Zepzelca, which has recently transitioned to frontline use. No specific financial metrics were disclosed during the call, indicating a focus on strategic developments rather than immediate financial results.
Reported metrics
| Metric | Value |
|---|---|
| PDUFA Date for Zanidatamab | August 25, 2026 (positive) |
| HER2-positive GEA Patients in U.S. | 8,000 (positive) |
| Zepzelca Market Transition | Transitioned to frontline use (positive) |
| Zanidatamab Peak Sales Estimate | $2 billion+ (neutral) |
Guidance from management
Management is optimistic about the upcoming launch of zanidatamab and its potential impact on revenue growth, particularly in the oncology segment. They are also preparing for a strong market entry with Zepzelca in frontline settings.
What management said
Joe, just really quickly. Little housekeeping. Rob and I going to make some forward-looking statements today. So please do refer to our SEC filings to reference those. We also may refer to earnings and guidance, if we do. We're referring to our most recent guidance as of our first quarter update and the same is true of any non-GAAP financial measures. You'll find a reconciliation in our first quarter earnings repo...
And Joe, in terms of differentiating BTC sales from GEA sales, they are different dosing regimens, but the GEA population is much larger. So we expect the growth that we see in Ziihera. It would be really driven by GEA uptake. It's very hard for us. Rob mentioned the overlap between the physicians. So it's hard for us to see sort of differences in prescriptions, BTC versus GEA. We'd expect it to be driven by and real...
What analysts pressed on
Analysts expressed concerns regarding the competitive landscape in oncology and the potential for market adoption of zanidatamab. There were questions about how quickly the market would embrace the new therapy and the differentiation from existing treatments.
Main topics on the call
- Oncology Pipeline Progress — Jazz Pharmaceuticals is making significant strides in its oncology pipeline, particularly with zanidatamab, which has received breakthrough designation and is on track for approval by August 25, 2026. Rob Iannone stated,...
- Zepzelca Performance — Zepzelca's transition to frontline use has shown strong performance, with management emphasizing its effectiveness in preventing rapid disease progression. Iannone noted, "Zepzelca going to have its best effect in front ...
- Regulatory Readiness — Management expressed confidence in their readiness for the zanidatamab launch, citing existing relationships with healthcare providers treating gastric cancer. Iannone mentioned, "We certainly are ready to launch by the ...
- Market Opportunity for GEA — The potential market for zanidatamab in frontline gastric cancer is estimated at around 8,000 HER2-positive patients in the U.S. Iannone stated, "There's a real impetus for docs to ensure that they know the HER2 status o...
Read the full Jazz Pharmaceuticals plc transcript (May 27, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc (JAZZ) is a publicly listed company in the Pharmaceuticals industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 101 calls on record spanning January 10, 2020 to June 3, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 101 Jazz Pharmaceuticals plc earnings call transcripts on record, spanning January 10, 2020 to June 3, 2026. Based on this history, Jazz Pharmaceuticals plc reports quarterly. The most recent call on file is dated June 3, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- JAZZ
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Calls on record
- 101
- First call
- January 10, 2020
- Most recent
- June 3, 2026
- Reporting cadence
- quarterly